Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

Serum microRNA profiles as prognostic or predictive markers in the multimodality treatment of patients with gastric cancer.

Sisic L, Vallböhmer D, Stoecklein NH, Blank S, Schmidt T, Driemel C, Möhlendick B, Knoefel WT, Odenthal M, Ott K.

Oncol Lett. 2015 Aug;10(2):869-874. Epub 2015 Jun 9.

2.

Serum microRNA profiles as prognostic/predictive markers in the multimodality therapy of locally advanced adenocarcinomas of the gastroesophageal junction.

Odenthal M, Hee J, Gockel I, Sisic L, Schmitz J, Stoecklein NH, Driemel C, Möhlendick B, Schmidt T, Knoefel WT, Lang H, Büttner R, Ott K, Vallböhmer D.

Int J Cancer. 2015 Jul 1;137(1):230-7. doi: 10.1002/ijc.29363. Epub 2014 Dec 3.

3.

MicroRNA profiling in locally advanced esophageal cancer indicates a high potential of miR-192 in prediction of multimodality therapy response.

Odenthal M, Bollschweiler E, Grimminger PP, Schröder W, Brabender J, Drebber U, Hölscher AH, Metzger R, Vallböhmer D.

Int J Cancer. 2013 Nov 15;133(10):2454-63. doi: 10.1002/ijc.28253. Epub 2013 Jun 3.

4.

Altered levels of the onco-microRNA 21 and the tumor-supressor microRNAs 143 and 145 in advanced rectal cancer indicate successful neoadjuvant chemoradiotherapy.

Drebber U, Lay M, Wedemeyer I, Vallböhmer D, Bollschweiler E, Brabender J, Mönig SP, Hölscher AH, Dienes HP, Odenthal M.

Int J Oncol. 2011 Aug;39(2):409-15. doi: 10.3892/ijo.2011.1036. Epub 2011 May 10.

PMID:
21567082
5.

Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.

Zhang JX, Song W, Chen ZH, Wei JH, Liao YJ, Lei J, Hu M, Chen GZ, Liao B, Lu J, Zhao HW, Chen W, He YL, Wang HY, Xie D, Luo JH.

Lancet Oncol. 2013 Dec;14(13):1295-306. doi: 10.1016/S1470-2045(13)70491-1. Epub 2013 Nov 13. Erratum in: Lancet Oncol. 2014 Jan;15(1):e4.

PMID:
24239208
6.

[18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer.

Vallböhmer D, Hölscher AH, Dietlein M, Bollschweiler E, Baldus SE, Mönig SP, Metzger R, Schicha H, Schmidt M.

Ann Surg. 2009 Dec;250(6):888-94.

PMID:
19953708
7.

MicroRNAs as a potential prognostic factor in gastric cancer.

Brenner B, Hoshen MB, Purim O, David MB, Ashkenazi K, Marshak G, Kundel Y, Brenner R, Morgenstern S, Halpern M, Rosenfeld N, Chajut A, Niv Y, Kushnir M.

World J Gastroenterol. 2011 Sep 21;17(35):3976-85. doi: 10.3748/wjg.v17.i35.3976.

8.

miRNA signature associated with outcome of gastric cancer patients following chemotherapy.

Kim CH, Kim HK, Rettig RL, Kim J, Lee ET, Aprelikova O, Choi IJ, Munroe DJ, Green JE.

BMC Med Genomics. 2011 Nov 23;4:79. doi: 10.1186/1755-8794-4-79.

9.

Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma.

Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, Jentzmik F, Miller K, Lein M, Kristiansen G, Jung K.

Int J Cancer. 2010 Mar 1;126(5):1166-76. doi: 10.1002/ijc.24827.

10.

Identification and characterization of tumor suppressor and oncogenic miRNAs in gastric cancer.

Chen Z, Liu X, Hu Z, Wang Y, Liu M, Liu X, Li H, Ji R, Guo Q, Zhou Y.

Oncol Lett. 2015 Jul;10(1):329-336. Epub 2015 May 6.

11.

microRNA expression profile in stage III colorectal cancer: circulating miR-18a and miR-29a as promising biomarkers.

Brunet Vega A, Pericay C, Moya I, Ferrer A, Dotor E, Pisa A, Casalots À, Serra-Aracil X, Oliva JC, Ruiz A, Saigí E.

Oncol Rep. 2013 Jul;30(1):320-6. doi: 10.3892/or.2013.2475. Epub 2013 May 15.

PMID:
23673725
12.

MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients.

Svoboda M, Sana J, Fabian P, Kocakova I, Gombosova J, Nekvindova J, Radova L, Vyzula R, Slaby O.

Radiat Oncol. 2012 Nov 20;7:195. doi: 10.1186/1748-717X-7-195.

13.

Serum microRNA-193b as a promising biomarker for prediction of chemoradiation sensitivity in esophageal squamous cell carcinoma patients.

Chan CM, Lai KKY, Ng EKO, Kiang MN, Kwok TWH, Wang HK, Chan KW, Law TT, Tong DK, Chan KT, Lee NP, Law S.

Oncol Lett. 2018 Mar;15(3):3273-3280. doi: 10.3892/ol.2017.7698. Epub 2017 Dec 27.

14.

Changes in circulating microRNAs after radiochemotherapy in head and neck cancer patients.

Summerer I, Niyazi M, Unger K, Pitea A, Zangen V, Hess J, Atkinson MJ, Belka C, Moertl S, Zitzelsberger H.

Radiat Oncol. 2013 Dec 28;8:296. doi: 10.1186/1748-717X-8-296. Erratum in: Radiat Oncol. 2015;10:102.

15.

microRNA expression profile in a large series of bladder tumors: identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancer.

Pignot G, Cizeron-Clairac G, Vacher S, Susini A, Tozlu S, Vieillefond A, Zerbib M, Lidereau R, Debre B, Amsellem-Ouazana D, Bieche I.

Int J Cancer. 2013 Jun 1;132(11):2479-91. doi: 10.1002/ijc.27949. Epub 2013 Feb 25.

16.

MicroRNA expression profiling of esophageal cancer before and after induction chemoradiotherapy.

Ko MA, Zehong G, Virtanen C, Guindi M, Waddell TK, Keshavjee S, Darling GE.

Ann Thorac Surg. 2012 Oct;94(4):1094-102; discussion 1102-3. doi: 10.1016/j.athoracsur.2012.04.145. Epub 2012 Aug 29.

PMID:
22939244
17.

MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications.

Busacca S, Germano S, De Cecco L, Rinaldi M, Comoglio F, Favero F, Murer B, Mutti L, Pierotti M, Gaudino G.

Am J Respir Cell Mol Biol. 2010 Mar;42(3):312-9. doi: 10.1165/rcmb.2009-0060OC. Epub 2009 Jun 5.

PMID:
19502386
18.

Tumor microRNA-29a expression and the risk of recurrence in stage II colon cancer.

Weissmann-Brenner A, Kushnir M, Lithwick Yanai G, Aharonov R, Gibori H, Purim O, Kundel Y, Morgenstern S, Halperin M, Niv Y, Brenner B.

Int J Oncol. 2012 Jun;40(6):2097-103. doi: 10.3892/ijo.2012.1403. Epub 2012 Mar 16.

PMID:
22426940
19.

Prognostic implications of serum microRNA-21 in colorectal cancer.

Menéndez P, Padilla D, Villarejo P, Palomino T, Nieto P, Menéndez JM, Rodríguez-Montes JA.

J Surg Oncol. 2013 Nov;108(6):369-73. doi: 10.1002/jso.23415. Epub 2013 Aug 23.

PMID:
23970420
20.

Gastric adenocarcinoma has a unique microRNA signature not present in esophageal adenocarcinoma.

Chen Z, Saad R, Jia P, Peng D, Zhu S, Washington MK, Zhao Z, Xu Z, El-Rifai W.

Cancer. 2013 Jun 1;119(11):1985-93. doi: 10.1002/cncr.28002. Epub 2013 Mar 1.

Supplemental Content

Support Center